Given the relatively small effect of the lead variant on SLC9A7 expression in the brain, it may thus be that more substantial reduction or pharmacological inhibition of SLC9A7 would prove to be an effective therapeutic strategy for AD. The gene discussed is SLC9A7; the disease is Alzheimer disease.